Protagonist Therapeutics PTGX EPS (Diluted)
EPS (Diluted) at other companies
Other financials
Where this comes from
Reported directly by Protagonist Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:EarningsPerShareDiluted.
The official record: Protagonist Therapeutics’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →
Ask your AI about Protagonist Therapeutics's eps (diluted).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Protagonist Therapeutics's EPS (diluted)?
- Protagonist Therapeutics (PTGX) reported EPS (diluted) of $0.05 in Q1 2026.
- How has Protagonist Therapeutics's EPS (diluted) changed year-over-year?
- Protagonist Therapeutics's EPS (diluted) increased by 126.3% year-over-year, from -$0.19 to $0.05.
- What is the long-term trend for Protagonist Therapeutics's EPS (diluted)?
- Over 3 years (2021 to 2025), Protagonist Therapeutics's EPS (diluted) has grown at a -8.6% compound annual growth rate (CAGR), from -$2.70 to -$2.06.
- What does EPS (diluted) mean?
- Net income divided by the weighted-average number of shares outstanding plus all potentially dilutive securities (stock options, convertibles, warrants). The most conservative EPS measure.